Stockreport

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Incorporated  (PRLD) 
PDF Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initia [Read more]